Physician profile
Joseph Mayus
NPI 1760424899
$4,439.38
in general payments reported to CMS, 2019-2025
20 companies · $38.73 in 2025
The $38.73 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,723 · 2020: $558 · 2021: $1,225 · 2022: $879 · 2024: $15.73 · 2025: $38.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $54.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $54.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $908.19 | 2019-2022 | |
| Abbvie INC. | $575.08 | 2019-2022 | |
| Amgen INC. | $501.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $356.33 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $304.32 | 2019-2022 | |
| Pfizer INC. | $271.43 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.93 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $238.23 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $216.88 | 2019 | |
| Celgene Corporation | $206.56 | 2019 | |
| Lilly USA, LLC | $186.69 | 2019-2021 | |
| Genentech USA, INC. | $88.89 | 2019-2022 | |
| Antares Pharma, INC. | $73.01 | 2019-2020 | |
| Ucb, INC. | $59.55 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $54.46 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $45.01 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $44.32 | 2022 | |
| Pacira Therapeutics, INC. | $26.59 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.38 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mayus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.